111 (NASDAQ:YI - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a research note issued on Thursday,Weiss Ratings reports.
111 Trading Up 4.3%
Shares of NASDAQ YI opened at $6.57 on Thursday. 111 has a 1-year low of $4.14 and a 1-year high of $11.90. The company has a 50-day moving average of $7.38 and a two-hundred day moving average of $7.78. The company has a market cap of $56.76 million, a PE ratio of -10.27 and a beta of 0.43.
111 (NASDAQ:YI - Get Free Report) last announced its quarterly earnings data on Thursday, June 19th. The company reported ($0.20) EPS for the quarter. The business had revenue of $486.35 million during the quarter.
Institutional Investors Weigh In On 111
Several large investors have recently modified their holdings of YI. Deuterium Capital Management LLC bought a new position in 111 during the 1st quarter worth about $81,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of 111 during the first quarter worth about $92,000. Finally, JPMorgan Chase & Co. boosted its position in shares of 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after buying an additional 305,339 shares during the period. 21.32% of the stock is currently owned by institutional investors.
111 Company Profile
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access